Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
IL-2 Antibody Inhibitor
Balekafusp alfa is an IgG1K human antibody specifically targeting interleukin-2 (IL-2). It exhibits anti-tumor activity, making it a valuable tool for cancer research and therapeutic studies. This reagent can aid in investigating the immunological mechanisms of IL-2 and its role in tumor progression. Additionally, researchers can utilize it to explore potential applications in immunotherapy and the modulation of immune responses. -
IL-17 Inhibitor
IL-17-IN-5 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.1 μM. This compound is designed for research applications related to inflammatory diseases, facilitating the study of IL-17's role in various pathophysiological processes. IL-17-IN-5 can aid in the development of therapeutic strategies targeting IL-17 signaling pathways. -
IL-1 Inhibitor
Triptoquinone B is a sesquiterpene alkaloid that functions as an interleukin-1 inhibitor. It exhibits significant inhibitory effects on the release of interleukin 1α and 1β from human peripheral mononuclear cells, making it a valuable reagent for studies focused on inflammatory processes and cytokine signaling. This compound is useful for research into immune responses and related therapeutic applications. -
CSF1R/Mer/Axl Inhibitor
Adrixetinib is a potent triple inhibitor targeting CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM respectively. This compound serves as an effective immune modulator by remodeling the tumor microenvironment, enhancing the presence of M1 macrophages and CD8⁺ T cells while reducing M2 macrophages and myeloid-derived suppressor cells (MDSCs). Additionally, Adrixetinib increases the expression of MHC class I and E-cadherin in tumor cells, demonstrating significant antitumor efficacy in syngeneic mouse models. It is relevant for research involving breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma. -
CD44-Hyaluronan Inhibitor
IGFBP-3 peptide is an 18-amino acid fragment of insulin-like growth factor binding protein-3, known to inhibit the interaction between CD44 and hyaluronan. This peptide effectively binds to Humanin and hyaluronan, thereby blocking their functional interactions. IGFBP-3 peptide serves as a useful tool for researching CD44-related signaling pathways and its role in cellular adhesion and migration. -
COX Inhibitor
(±)-Aiphanol is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-1 (IC50 = 1.9 μM) and COX-2 (IC50 = 9.9 μM). This compound displays significant anti-inflammatory properties and further inhibits vascular endothelial growth factor receptor 2 (VEGFR2) with an IC50 of 0.92 μM. By impeding both COX-2 and VEGFR2 pathways, (±)-Aiphanol effectively blocks angiogenesis and induces apoptosis, making it a valuable tool in the study of inflammatory diseases and cancer research. The compound demonstrates oral bioactivity, enhancing its potential for in vivo applications. -
Keap1-Nrf2 Inhibitor
Keap1-Nrf2-IN-11 is a potent inhibitor of the Keap1-Nrf2 interaction, exhibiting a KD2 value of 0.21 nM. This compound effectively reduces the production of reactive oxygen species (ROS) and nitric oxide (NO), as well as downregulating the expression of tumor necrosis factor-alpha (TNF-α). By promoting Nrf2 nuclear translocation, Keap1-Nrf2-IN-11 demonstrates significant anti-inflammatory properties, making it a valuable tool for research in inflammation-related pathways. -
Complement Inhibitor
3-Phenoxybenzaldehyde is a compound identified as a complement inhibitor, exhibiting weak inhibition of the classical pathway of the complement system. This compound demonstrates hemolytic activity, making it relevant for studies related to immune response modulation and complement pathway research. Its applications extend to investigations in autoimmune diseases and therapies targeting complement-mediated cytotoxicity. -
C5 Complement Inhibitor
Avacincaptad pegol is a pegylated RNA aptamer that selectively inhibits complement component C5. By preventing the cleavage of C5 into pro-inflammatory fragments C5a and C5b, this compound mitigates inflammatory cell recruitment and reduces retinal cell damage. Avacincaptad pegol has demonstrated potential in slowing the progression of geographic atrophy (GA) lesions and decreasing the risk of vision loss, making it a valuable tool for research involving age-related macular degeneration (AMD). -
Complement System Inhibitor
Factor B-IN-1 is an inhibitor of Factor B, targeting the complement system to modulate its activity. This compound demonstrates significant inhibition of the alternative pathway of complement activation, making it a valuable tool for studying complement-mediated diseases and immune responses. Factor B-IN-1 is suitable for use in research applications focused on therapeutic interventions and the development of complement-targeted therapies. -
Complement Factor D Inhibitor
Complement Factor D-IN-2 is an inhibitor targeting complement factor D, effectively interrupting the complement cascade at a critical juncture within the alternative complement pathway. By inhibiting factor D, this compound presents valuable opportunities for investigating the role of complement activation in autoimmune diseases. Researchers can utilize Complement Factor D-IN-2 to explore therapeutic strategies aimed at modulating immune responses and mitigating the progression of complement-mediated pathologies. -
Complement Factor D Inhibitor
Refinicopan is a selective inhibitor of complement factor D, demonstrating an IC50 of 10 nM. This compound effectively inhibits rabbit erythrocyte hemolysis with an IC50 of 41 nM, indicating its capacity to modulate complement-mediated processes. Refinicopan's favorable pharmacokinetic and pharmacodynamic properties make it a valuable tool for investigating complement-related disorders and potential therapeutic interventions. -
Complement Protein C5 Inhibitor
Vensobafusp alfa is a fusion protein that targets complement protein C5, functioning as a potent inhibitor. It combines an IgG4 monoclonal antibody directed against C5 with the complement factor H 1-5 domain, demonstrating significant anti-inflammatory and immunomodulatory properties. This reagent is applicable in the study of complement-mediated pathologies and therapeutic strategies targeting inflammatory conditions. -
Complement System Inhibitor
Bisphenol A bissulfate disodium is a complement system inhibitor with a significant role in modulating immune responses. This compound exhibits complement-inhibiting activity, demonstrating an IC50 value of 247 μM. It is utilized in research applications aimed at understanding the complement pathway and its implications in various diseases, making it a valuable tool in immunological studies. -
Complement inhibitor
Bisphenol S disulfate disodium is a complement inhibitor that exhibits a half-maximal inhibitory concentration (IC50) of 660 μM. This compound is utilized in research applications aiming to explore complement-mediated pathways and their roles in various biological processes and diseases. Its ability to modulate complement activity makes it a valuable tool for studies involving immune response and inflammation. -
TLR7/8 Inhibitor
Enpatoran is a potent and orally active dual inhibitor of Toll-like receptors 7 and 8, exhibiting IC50 values of 11.1 nM and 24.1 nM, respectively, in HEK293 cells. This compound is selective, showing no activity against TLR3, TLR4, or TLR9. Enpatoran effectively blocks both synthetic and natural RNA ligands, demonstrating excellent pharmacokinetic properties in vivo. It is a valuable tool for research focused on modulating innate and adaptive immune responses related to autoimmunity. -
TLR3 Inhibitor
CU-CPT 4a is a selective inhibitor of TLR3 signaling, effectively blocking the downstream pathways activated by the TLR3/dsRNA complex. This compound suppresses the production of pro-inflammatory cytokines, including TNF-α and IL-1β, making it a valuable tool for research into immune responses and inflammation. CU-CPT 4a is suitable for studies focused on modulating TLR3-related signaling pathways in various disease models. -
SARM1 Activator/CD38 Inhibitor
Sulfo-ara-F-NMN is a selective SARM1 activator and CD38 inhibitor, functioning as a mimetic of nicotinamide mononucleotide (NMN). It effectively activates SARM1 while inhibiting CD38, with an IC50 of approximately 10 μM. This compound is valuable for research applications focused on the modulation of intracellular cyclic ADP-ribose (cADPR) production and the exploration of pathways involving SARM1 and CD38 in cellular signaling. -
TLR7/TLR9 Inhibitor
AT791 is a potent inhibitor of Toll-like receptors 7 and 9 (TLR7/TLR9), demonstrating strong oral bioavailability. This compound effectively blocks TLR7 and TLR9 signaling pathways in a range of human and murine cell types, as well as inhibiting DNA-TLR9 interactions in vitro. AT791 is applicable in research focused on immune modulation and the characterization of TLR-mediated signaling. -
TLR3/7/9 Inhibitor
ODN 2088 is a potent inhibitor of Toll-like receptors 3, 7, and 9 (TLR3, TLR7, TLR9), demonstrating a strong capacity to modulate immune responses. This compound effectively suppresses the release of key pro-inflammatory cytokines, including interferon-alpha (IFN-α) and interleukin-6 (IL-6), without exhibiting cytotoxic effects. ODN 2088 is valuable for research applications focused on understanding TLR-mediated signaling pathways and their roles in various immune-related conditions. -
Toll-like Receptor (TLR) Inhibitor
Okanin is a potent Toll-like Receptor (TLR) inhibitor derived from the flowering plant Coreopsis tinctoria. It exhibits significant biological activity by attenuating lipopolysaccharide (LPS)-induced microglial activation via the inhibition of the TLR4/NF-κB signaling pathway. This compound is useful for research applications focusing on neuroinflammation and the modulation of immune responses in microglial cells. -
TLR7/8 Inhibitor
Enpatoran hydrochloride is a dual inhibitor of Toll-like receptors 7 and 8, demonstrating potent activity with IC50 values of 11.1 nM and 24.1 nM, respectively, in HEK293 cells. This compound is selectively inactive against TLR3, TLR4, and TLR9, effectively blocking both synthetic and natural RNA ligands. Enpatoran hydrochloride exhibits favorable pharmacokinetic profile in vivo, making it a valuable tool for research into innate and adaptive autoimmunity pathways. -
TLR9 Inhibitor
TLR9-IN-1 is a potent and selective inhibitor of Toll-like receptor 9 (TLR9), exhibiting an IC50 value of 7 nM for human TLR9. This compound is valuable for studying diseases linked to aberrant immune responses, making it an important tool in immunological research and therapeutic development. Researchers can utilize TLR9-IN-1 to explore the modulation of TLR9 pathways in various inflammatory and autoimmune conditions. -
TLR7/TLR8 Inhibitor
TLR7/8-IN-1 is a potent inhibitor of Toll-like receptors 7 and 8, which play critical roles in the immune response. This compound exhibits strong potential in modulating inflammatory pathways associated with autoimmune diseases. It serves as a valuable tool for researchers investigating the therapeutic targeting of TLR7 and TLR8 in various immunological studies. -
TLR4 Inhibitor/PROTAC Linker
TLR4-IN-C34-C2-COOH is a TLR4 inhibitor that serves as a PROTAC linker. It demonstrates significant potential in the modulation of inflammatory responses, particularly in studies involving acute myocardial injury. By targeting TLR4 in enterocytes and macrophages, TLR4-IN-C34-C2-COOH effectively reduces systemic inflammation in murine models of endotoxemia and necrotizing enterocolitis, making it a valuable tool for research in inflammation-related pathways. -
Inflammatory Cell Activation Inhibitor
CI-959 is an inhibitor of inflammatory cell activation, primarily targeting signaling pathways involved in immune response modulation. It demonstrates significant anti-inflammatory and anti-allergic properties by reducing the production of reactive oxygen species in neutrophils, inhibiting neutrophil adhesion, and blocking histamine release from mast cells. CI-959 also effectively suppresses the release of inflammatory mediators, including histamine, leukotrienes, and thromboxane, from guinea pig and human lung tissues. This compound is valuable for research focused on inflammatory and allergic diseases, particularly asthma. -
xanthine oxidase inhibitor
Allopurinol is a structural isomer of hypoxanthine (a naturally occurring purine in the body) and is an inhibitor of the enzyme xanthine oxidase. -
COX-2 inhibitor
Celecoxib is a sulfa non-steroidal anti-inflammatory drug (NSAID) and selective COX-2 inhibitor used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis.
-
Dihydropyrimidinase Inhibitor
Dihydromyricetin (Ampelopsin (flavanol); Ampeloptin) is a natural antioxidant with good prospects. -
COX inhibitor
Diclofenac Sodium is a non-selective COX inhibitor with IC50 of 0.5 μg/ml and 0.5 μg/ml for COX-1 and -2 in intact cells, respectively, used as a nonsteroidal anti-inflammatory drug (NSAID) to relieve pain and reduce swelling in flammation. -
xanthine oxidase inhibitor
Febuxostat is a non-purine inhibitor of xanthine oxidase (Ki = 1.2 nM). -
COX-1 inhibitor
Ibuprofen Lysine(Motrin) is a non-steroidal anti-inflammatory drug. -
NLRP3 inflammasome inhibitor
Isoliquiritigenin is a licorice chalconoid, a type of natural phenols that is currently under experimentation phase testing for use as a cancer treatment as well as an aide for cocaine addiction. -
COX-1/COX-2 inhibitor
Ketoprofen (RP-19583) is a non-steroidal antiinflammatory agent, acting as a potent inhibitor of COX, with IC50s of 2 nM and 26 nM for COX-1 and COX-2 in human blood monocytes, respectively. -
IMPDH inhibitor
Mycophenolate mofetil is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH) in purine biosynthesis (specifically guanine synthesis) which is necessary for the growth of T cells and B cells. -
COX inhibitor
Naproxen sodium is a non-selective cyclooxygenase (COX) inhibitor that displays anti-inflammatory, antipyretic and analgesic effects. Has a neuroprotective role against colchicine-induced cognitive impairment and oxidative stress. -
COX inhibitor
Phenylbutazone is a compound of research interest as an anti-inflammatory and anti-proliferative agent. -
COX inhibitor
Piroxicam is an effective and potent inhibitor of prostaglandin synthesis and a Cox-1 and Cox-2 inhibitor. -
COX inhibitor
Sulindac is a non-steroidal COX inhibitor, which potently inhibits prostaglandin synthesis, used in the treatment of acute or chronic inflammatory conditions -
Primates' C3 Inhibitor
Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates' complement system. Compstatin exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively.
-
Complement factor C3 inhibitor
POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research -
CKLF1/CCL17 inhibitor
CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4. -
IL-12/IL-23 inhibitor
Apilimod (STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively.
